Do all dry powder inhalers show the same pharmaceutical performance?
- 8 November 2005
- journal article
- review article
- Published by Hindawi Limited in International Journal of Clinical Practice
- Vol. 59 (s149), 7-12
- https://doi.org/10.1111/j.1368-504x.2005.00721.x
Abstract
Important measures of pharmaceutical performance of dry powder inhalers include total emitted dose (TED, the quantity of drug emitted from the device when used at a fixed flow rate, typically 60 l/min or the flow rate achieved at a pressure drop of 4 kPa) and fine particle mass (FPM, the quantity of drug with small particles, typically with an aerodynamic diameter of less than 5 microns emitted from the device at a fixed flow rate). There is a wide range of dry powder inhalers available. The complexity of design decisions means that dry powder inhalers are very diverse, with identical designs unlikely. It is not surprising therefore that evidence from in vitro studies shows considerable variation in pharmaceutical performance of dry powder inhalers. Although neither TED nor FPM can accurately predict in vivo performance, it may be expected that highly variable or inhalation flow sensitive in vitro behaviour will be reflected in variable performance when used by patients.Keywords
This publication has 9 references indexed in Scilit:
- In Vitro Aerosol Performance and Dose Uniformity between the Foradile® Aerolizer® and the Oxis® Turbuhaler®Journal of Aerosol Medicine, 2001
- A Critical Comparison of the Dose Delivery Characteristics of Four Alternative Inhalation Devices Delivering Salbutamol: Pressurized Metered Dose Inhaler,DiskusInhaler,DiskhalerInhaler, andTurbuhalerInhalerJournal of Aerosol Medicine, 1999
- Fine particle mass from the Diskus inhaler and Turbuhaler inhaler in children with asthmaEuropean Respiratory Journal, 1998
- A comparison of the performance of two modern multidose dry powder asthma inhalersRespiratory Medicine, 1998
- In vitro evaluation of dry powder inhalers II: influence of carrier particle size and concentration on in vitro depositionInternational Journal of Pharmaceutics, 1997
- In vitro evaluation of dry powder inhalers I: drug deposition of commonly used devicesInternational Journal of Pharmaceutics, 1997
- Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers Part 2: Effect of peak flow rate (PIFR) and inspiration time on the in vitro drug release from three different types of commercial dry powder inhalersInternational Journal of Pharmaceutics, 1996
- Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers Part 1. Inhalation characteristics, work of breathing and volunteers' preference in dependence of the inhaler resistanceInternational Journal of Pharmaceutics, 1996
- Dose emissions from marketed dry powder inhalersInternational Journal of Pharmaceutics, 1995